

## DIAGNOSTIC CHECKLIST

Assessment	Findings Suggestive of Plasminogen Deficiency Type 1 (PLGD-1)	Comments										
<input type="checkbox"/>	Patient History / Clinical Evaluation	<ul style="list-style-type: none"> <li>• Recurrent ear infections; hearing loss</li> <li>• Gum growths/lesions</li> <li>• History of eyelid growths (pseudomembranous lesions); history of frequent eye infections;</li> <li>• Asthma; hoarseness of voice; recurrent coughing; trouble breathing; recurrent pneumonia</li> <li>• GI symptoms: recurrent stomach ulcers, IBD</li> <li>• Poor wound healing; juvenile colloid milia</li> <li>• Symptoms of hydrocephalus (neonates only) or diagnosis of Dandy-Walker malformation</li> <li>• Female dysmenorrhea or infertility of unknown cause</li> </ul>	<ul style="list-style-type: none"> <li>• PLGD-1 is the most common cause of ligneous conjunctivitis (LC)<sup>1</sup></li> <li>• LC is the most common symptoms in PLGD-1, followed by ligneous gingivitis<sup>1</sup></li> <li>• Other symptom locations include the ears, nose, respiratory tract, gastrointestinal tract, urinary tract, and female reproductive tract<sup>1</sup></li> <li>• A history of, or current findings of, the symptoms listed at left should suggest evaluation for the diagnosis of PLGD-1</li> </ul>									
<input type="checkbox"/>	Family medical history	Confirmed diagnosis of PLGD-1 in a first degree relative (parents, siblings)	Evaluate all siblings regardless of symptoms PLGD-1 is inherited in an autosomal recessive fashion Carriers will have lower levels of plasminogen activity, but will likely be asymptomatic Siblings may be asymptomatic but be affected									
<input type="checkbox"/>	Plasminogen activity functional assays 4 <ul style="list-style-type: none"> <li>• Chromogenic assay</li> <li>• Clot lysis time</li> </ul>	Activity level less than normal for the individual lab where test was run	Activity level $\leq$ 45% was used as the cut off for clinical trials, however affected patients have been noted to have levels higher than this cut off value									
<input type="checkbox"/>	Plasminogen antigen assays	Antigen level less than normal for the individual lab where test was run	<ul style="list-style-type: none"> <li>• Antigen assays together with activity assays distinguish PLGD-1 from PLGD-2:</li> </ul> <table style="margin-left: 40px; border-collapse: collapse;"> <thead> <tr> <th></th> <th style="text-align: center;"><u>Activity</u></th> <th style="text-align: center;"><u>Antigen</u></th> </tr> </thead> <tbody> <tr> <td><b>PLGD-1</b></td> <td style="text-align: center;">Low</td> <td style="text-align: center;">Low</td> </tr> <tr> <td><b>PLGD-2</b></td> <td style="text-align: center;">Low</td> <td style="text-align: center;">Normal</td> </tr> </tbody> </table> <ul style="list-style-type: none"> <li>• Patients with PLGD-1 will be symptomatic, however patients with PLGD-2 do not develop lesions and will not need treatment</li> </ul>		<u>Activity</u>	<u>Antigen</u>	<b>PLGD-1</b>	Low	Low	<b>PLGD-2</b>	Low	Normal
	<u>Activity</u>	<u>Antigen</u>										
<b>PLGD-1</b>	Low	Low										
<b>PLGD-2</b>	Low	Normal										
<input type="checkbox"/>	Molecular Genetic Test***	Mutations in PLG gene	Genetic testing <b>is NOT required</b> as part of the diagnostic evaluation for PLGD-1; there is yet no known correlation between genetic mutation and symptom development or disease severity									
<input type="checkbox"/>	Lesion Biopsy***	<ul style="list-style-type: none"> <li>• Eroded epithelium with fibrin-rich deposits<sup>1</sup></li> <li>• Granulation tissue<sup>1</sup></li> </ul>	Surgical interventions, including lesion biopsy, <b>should NOT be performed</b> as part of a diagnostic evaluation, as these interventions can worsen patient symptoms, cause rapid lesion recurrence after intervention, and contribute to permanent scarring or end organ damage									

\*\*\* NOT Required for Diagnosis

References: 1. Schuster V, Seregard S. Ligneous conjunctivitis. *Surv Ophthalmol.* 2003;48(4):369-88. 2. Martin-Fernandez L, Marco P, Corrales I, et al. The unravelling of the genetic architecture of plasminogen deficiency and its relation to thrombotic disease. *Sci Rep.* 2016;6:39255. doi: 10.1038/srep39255. 3. Plasminogen deficiency. Indiana Hemophilia & Thrombosis Center website. <https://www.ihtc.org/plasminogen-deficiency>. Accessed January 30, 2022. 4. Plasminogen (PLG). DiaPharma website. <https://diapharma.com/plasminogen-plg>. Accessed January 30, 2022. 5. Schuster V, Hügler B, Tefs K. Plasminogen deficiency. *J Thromb Haemost.* 2007; 5(12):2315-22. 6. Tefs K, Gueorguieva M, Klammt J, et al. Molecular and clinical spectrum of type plasminogen deficiency: A series of 50 patients. *Blood.* 2006;108(9):3021-6. 7. Shapiro AD, Menegatti M, Palla R, et al. An international registry of patients with plasminogen deficiency (HISTORY). *Haematologica.* 2020;105(3):554-561.